The company has received final approval from the US Food Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Fesoterodine Fumarate extended-release tablets in strength of 4 mg and 8 mg, the drug firm said in a statement.
The company has received final approval from the US Food Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Fesoterodine Fumarate extended-release tablets in strength of 4 mg and 8 mg, the drug firm said in a statement. The company has received final approval from the US Food Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Fesoterodine Fumarate extended-release tablets in strength of 4 mg and 8 mg, the drug firm said in a statement. Moneycontrol Latest News Read More
हिन्दी 
English